Fatal late-onset pneumocystis pneumonia after rituximab: Administration for posttransplantation recurrence of focal segmental glomerulosclerosis - Case report

Transplantation Proceedings

Volumn 46, Issue 8, 2014, Pages 2908-2911

  Deborska Materkowska D ^a   Kozinska Przybyl O ^a   Mikaszewska Sokolewicz, M ^a   Durlik, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLEMASTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCONAZOLE; GANCICLOVIR; IMIPENEM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PHENAZOPYRIDINE PLUS SULFAMETHOXAZOLE PLUS TRIMETHOPRIM; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; VANCOMYCIN; VORICONAZOLE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CASE REPORT; CONFERENCE PAPER; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FLUID RESUSCITATION; FOCAL GLOMERULOSCLEROSIS; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OFF LABEL DRUG USE; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PROTEINURIA; RECURRENT DISEASE; ADVERSE EFFECTS; CHEMICALLY INDUCED; FATALITY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT SURVIVAL; IMMUNOCOMPROMISED PATIENT; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDY; YOUNG ADULT;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FATAL OUTCOME; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PNEUMONIA, PNEUMOCYSTIS; PROSPECTIVE STUDIES; RECURRENCE; YOUNG ADULT;

EID: 84910120608     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.09.010     Document Type: Conference Paper

References (31)

1. M. Artero, C. Biava, and W. Amend Recurrent focal glomerulosclerosis: natural history and response to therapy Am J Med 92 1992 375 383
2. F. Vincenti, and G.M. Ghiggeri New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis Am J Transplant 5 2005 1179 1185
3. R. Bertelli, F. Ginevri, and G. Caridi Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin Am J Kidney Dis 41 2003 1314 1318
4. G. Moroni, B. Gallelli, and S. Quaglini Long-term outcome of renal transplantation in adults with focal segmental glomerulosclerosis Transpl Int 23 2010 208 216
5. A. Mayrier Treatment of focal segmental glomerulosclerosis Expert Opin Pharmacother 6 2005 1539 1549
6. L. Dello Strologo, I. Guzzo, and C. Laurenzi Use of rituximab in focal glomerulosclerosis relapses after renal transplantation Transplantation 3 2009 417 420
7. M. Sato, S. Ito, and M. Ogura Atypical Pneumocystis jirovecii pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome Pediatr Nephrol 28 2013 145 149
8. E. Shelton, M. Yong, and S. Cohney Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection Nephrology (Carlton) 14 2009 696 699
9. S. Kamel, S. O'Connor, and N. Lee High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, Adriamycin, vincristine, and prednisone Leuk Lymphoma 51 2010 797 801
10. H. Katsuya, J. Suzumiya, and H. Sasaki Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma Leuk Lymphoma 50 2009 1818 1823
11. D. Kumar, S. Gourishankar, and T. Mueller Pneumocystis jirovecii pneumonia after rituximab therapy for antibody mediated rejection in a renal transplant recipient Transpl Infect Dis 11 2009 167 170
12. S.M. Gordon, S.P. LaRosa, and S. Kalmadi Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 28 1999 240 246
13. S. Le Gal, C. Damiani, and A. Rouille A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii Clin Infect Dis 54 2012 e62 71
14. B.L. Kasiske, M.G. Zeier, and J.R. Chapman KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary Kidney Int 77 2010 299 311
15. H. Yazaki, N. Goto, and K. Uchida Outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients: P. jirovecii is contagious to the susceptible host Transplantation 88 2009 380 385
16. M.G.J. de Boer, F.P. Kroon, and S. le Cessie Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis Transpl Infect Dis 13 2011 559 569
17. T.R. Franson, H.M. Kauffman Jr., and M.B. Adams Cyclosporine therapy and refractory Pneumocystis carinii pneumonia. A potential association Arch Surg 122 1987 1034 1035
18. P.D. Walzer, M. LaBine, and T.J. Redington Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia J Immunol 133 1984 2502 2508
19. J.A. Fishman Prevention of infection caused by Pneumocystis carinii in transplant recipients Clin Infect Dis 33 2001 1397 1405
20. M.S. Cragg, C.A. Walshe, and A.O. Ivanov The biology of CD20 and its potential as a target for mAb therapy Curr Dir Autoimmun 8 2005 140 174
21. K. Nozu, K. Iijima, and M. Fujisawa Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephritic syndrome Pediatr Nephrol 20911 2005 1660 1663
22. L.J. Hickson, M. Gera, and H. Amer Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence Transplantation 87 2009 1232 1239
23. Y. Moriya, K. Yamaji, and Y. Kanai The effectiveness of intravenous human immunoglobulin treatment after plasmapheresis in restoring serum immunoglobulin levels: a preliminary study Ther Apher 6 2002 154 158
24. F.E. Lund, K. Schuer, and M. Hollifield Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody J Immunol 171 2003 1423 1430
25. F.E. Lund, M. Hollifield, and K. Schuer B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection J Immunol 176 2006 6147 6154
26. E. Wilk, T. Witte, and N. Marquardt Depletion of functionally active CD20 T cells by rituximab treatment Arthritis Rheum 60 2009 3563 3571
27. S. Aksoy, O. Dizdar, and M. Hayran Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis Leuk Lymphoma 50 2009 357 365
28. A. Kolstad, H. Holte, and A. Fossa Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen Haematologica 92 2007 139 140
29. E. Hardak, I. Oren, and E.J. Dann The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience Acta Haematol 127 2012 110 114
30. H. Genberg, A. Hansson, and A. Wernerson Pharmacodynamics of rituximab in kidney transplantation Transplantation 27 2007 S33 36
31. S.A. Grim, T. Pham, and J. Thielke Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal trans plant recipients Clin Transplant 21 2007 628 632